



TcLand SA announces a company split into two autonomous branches of activity.

Nantes, December 10th, 2007 – TcLand SA, a pioneering biotechnology company in the field of personalized medicine in transplantation and auto-immune disease founded in 2002, has today announced the transfer of all its assets and liabilities into two independent companies, with immediate effect.

TcLand Pharma SAS, a company recently acquired by TcLand SA, specializes in the development of therapeutic molecules (fusion proteins and monoclonal antibodies) in the field of transplantation and auto-immune diseases (Multiple Sclerosis, Rheumatoid Arthritis and Inflammatory Bowel Diseases). All of TcLand SA's assets and liabilities related to therapeutic programs (including two anti-IL mAbs and the anti-CD28 research program) have been transferred to TcLand Pharma SAS.

TcLand Expression SA, previously TcLand SA, will henceforth focus fully on the discovery, development and commercialization of gene expression biomarkers and immune-profiling in transplantation and auto-immune disease. The company's core activity is the development of gene expression biomarkers in kidney transplantation - a research program initiated in 2002 which has won the company a pioneering position in the fast-expanding field of personalized medicine. The company expects to commercialize its first biomarkers no later than 2009 in Europe and 2010 in the USA. TcLand Expression SA benefits from a strong research base, with privileged access to one of Europe's leading kidney and pancreas transplantation research and clinical centers (ITERT, INSERM U643 Nantes, headed by Prof. Jean-Paul Soulillou). TcLand Expression SA already generates revenues through provision of innovative immune-monitoring services to a base of 35 customers in Europe, the USA and Australia.

“This split is a major corporate development milestone for TcLand; it simultaneously strengthens two independent companies focused on two different business areas. The skills, expertise, financial needs, company focus and product development cycles are all different. For example, TcLand Expression is strengthening its management team not only in areas related to molecular biology and bioinformatics but also in terms of specific clinical development, regulatory and marketing skills for diagnostics products. This split paves the way to our future success”, commented Alain Huriez MD, co-founder and Chairman & CEO of TcLand Expression SA and Chairman of TcLand Pharma SAS.

For more information on both companies, please visit:
www.tcland-expression.com & www.tcland-pharma.com

###

This press release may contain forward-looking statements. As such, they do not guarantee future performance; there are risks and uncertainties. Future scientific, preclinical, clinical, regulatory, manufacturing, financial, commercial, business outcomes may be substantially different from those suggested by the forward-looking statements. The forward-looking statements are effective only as per the date at the top of this press release.

Press contacts

Alizé PR

Caroline Carmagnol

+33 (0)6 64 18 99 59

caroline@alizerp.com

TcLand Expression SA – ahuriez@tcland-expression.com